Conference · Basel, Switzerland
Oncology Drug Induced Cardiotoxicity Conference
Health · Wellness
Key numbers
- Editions on record
- 1first in 2015
About Oncology Drug Induced Cardiotoxicity Conference
There is a growing understanding of the overlap between therapeutic cancer targets and the healthy cardiovascular system. An increasing number of oncology drugs are now known to potentially affect the myocardium and other cardiovascular structures adversely. Preclinical development is tasked to assess the on-target and off-target effects of therapeutic candidates, and to develop compound-specific algorithms and biomarker programmes to support safe clinical development.
An improved understanding of these mechanisms and their early detection will enable the early development of diagnostic and mitigation strategies in the clinic, allowing high-need cancer treatment to reach and benefit patients. As patient survivals increase in oncology, risk-based safety surveillance is needed to identify late onset cardiotoxicity.
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2015 | 18–19 May 2015 | Pullman Basel Europe Basel, Switzerland | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.
Questions
When is Oncology Drug Induced Cardiotoxicity Conference?
The next dates haven't been confirmed. The last edition we have on record was 18–19 May 2015.
Where is it held?
The last edition we have was at Pullman Basel Europe, Basel, Switzerland.